IDRX-42 in metastatic and/or unresectable GIST

 

Trial name: IDRX in advanced GIST
Agents: IDRX-42
Phase I/Ib
Status Recruiting
Sponsor IDRx Inc.

 

This is a Phase 1/1b open-label study of IDRX-42 in metastatic and/or unresectable GIST.

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Adult patients with confirmed diagnosis of unresectable or metastatic GIST
  • Patients with a GIST tumor that has progressed under at least one previous therapy including imatinib
  • Overall health status of the patient has to be good (ECOG performance status 0 or 1)

WHAT is the key question that this trial is attempting to answer?

 The study evaluates the safety, tolerability, and preliminary efficacy of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in GIST and potentially help other patients with this disease. The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is currently active in the US, Belgium, Germany, the Netherlands and Spain, but will be opened in more countries in due course.

Please check for current information here.

Study contact:

  • IDRX Clinical Operations
  • Phone: +1339-234-7028
  • Email: clinicaltrials@idrx.com

STUDY DESIGN: What does the study look like?

 The study consists of 2 parts.

In Phase 1 the best dose is being assessed. In Phase 1b, there are several groups of participants defined by numbers of lines of prior GIST therapy (including investigational treatments).

HOW do I get more information?

 Patient organizations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving GIST and/or sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken